| 5.05 -0.4 (-7.34%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.25 |
1-year : | 6.79 |
| Resists | First : | 5.35 |
Second : | 5.82 |
| Pivot price | 5.2  |
|||
| Supports | First : | 4.59 |
Second : | 3.82 |
| MAs | MA(5) : | 5.47 |
MA(20) : | 5.17 |
| MA(100) : | 5.83 |
MA(250) : | 4.47 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 55.8 |
D(3) : | 72.1 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 10.07 | Low : | 1.1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IMRX ] has closed above bottom band by 34.6%. Bollinger Bands are 42.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.53 - 5.56 | 5.56 - 5.59 |
| Low: | 4.85 - 4.88 | 4.88 - 4.91 |
| Close: | 5 - 5.06 | 5.06 - 5.1 |
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Mon, 09 Mar 2026
Immuneering Corporation (IMRX) PT Lowered to $12; Piper Sandler: 'We Remain Buyers' - StreetInsider
Mon, 02 Mar 2026
Late-stage cancer firm Immuneering to outline pipeline at Miami investor event - Stock Titan
Thu, 26 Feb 2026
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Sat, 10 Jan 2026
Why Immuneering (IMRX) Is Down 29.7% After Phase 2a Pancreatic Data Versus Historical Benchmarks And Phase 3 Plan - simplywall.st
Thu, 08 Jan 2026
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data (NASDAQ:IMRX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 17.8 (%) |
| Held by Institutions | 50.7 (%) |
| Shares Short | 11,420 (K) |
| Shares Short P.Month | 11,200 (K) |
| EPS | -1.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.58 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26 % |
| Return on Equity (ttm) | -43.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -2.83 |
| PEG Ratio | 0 |
| Price to Book value | 1.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|